> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – April 2012

Loading EJC News Focus video

Scientific advances in breast cancer which will not only improve outcomes but also make a real difference to patients’ experiences of care, were presented at the 8th European Breast Cancer Conference (EBCC-8) in Vienna, Austria (21-24 March 2012). Highlights included a study of ultrasound-guided surgery, which led to a significant decrease in re-excisions, mastectomies and extra  radiotherapy (compared with standard palpation-guided excisions); and new data on subcutaneous trastuzumab, which gave the same benefits as the drug given intravenously, while being more convenient for both patients and clinicians, saving time and resources all round.

In this month’s EJC News Focus, EJC’s Breast Cancer Editor, Kathy Pritchard (Sunnybrook Regional Cancer Center, Toronto, Ontario) discusses these and other key presentations.


Nicole Krekel. Ultrasound-guided surgery. EBCC-8, LBA#1

Michael Gnant. Latest results from BOLERO 2: everolimus plus exemestane improves bone health in postmenopausal women. EBCC-8, LBA#3

Stephen Johnston. First results of SoFEa trial: fulvestrant alone or with concomitant anastrole vs exemestane following progression on non-steroidal aromatase inhibitor. EBCC-8, LBA#2 (See also previous studies on fulvestrant: Jonas Bergh et al. FACT study. doi: 10.1200/JCO.2011.38.1095; Rita Mehta et al. SWOG S0226. San Antonio Breast Cancer Symposium, Dec 2011 #S1-1)

Christian Jackisch. Subcutaneous administration of trastuzumab. EBCC-8, Best Abstract #1